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Background
The region of HIV-1 envelope glycoprotein gp120 that
engages its primary cellular receptor CD4, forms a site of
vulnerability to neutralizing antibodies. The monoclonal
antibody b12 exploits the conservation and accessibility
of the CD4-binding site to neutralize many, though not
all HIV-1 isolates.
Methods
To understand the basis of viral resistance to b12 neutral-
ization, we used the atomic-level definition of b12-gp120
contact sites to study a panel of diverse circulating viruses.
A combination of sequence analysis, computational mod-
eling, and site-directed mutagenesis were used to deter-
mine the influence of amino-acid variants on binding and
neutralization by b12.
Results
We found that several substitutions within the dominant
b12-contact surface, called the CD4-binding loop, medi-
ated b12 resistance and that these substitutions resided
just proximal to the known CD4-contact surface. This
explained how primary isolates of HIV-1 were able to
evade b12 neutralization while retaining functional bind-
ing to CD4. In addition, some viruses were resistant to
b12 despite minimal sequence variation at b12-contact
sites. Such neutralization resistance could usually be
reversed by alterations at residues thought to influence the
quaternary configuration of the viral envelope spike.
Conclusion
Among circulating isolates of HIV-1, b12 resistance arises
from a combination of sequence variation at key b12-con-
tact residues, which are proximal to but not part of the
CD4-contact surface, and alterations in the native config-
uration of the viral envelope spike, which serves to restrict
b12 access. These data inform vaccine design by explain-
ing how the virus can escape from neutralizing antibodies
yet retain functional binding to its primary cellular recep-
tor. Researchers may be able to use this information to
design modifications of vaccine immunogens to better
induce neutralizing antibodies to vulnerable regions of
HIV-1.
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